Rekovar Secures Central IRB Approval Through WCG for Groundbreaking NAS Monitoring System Clinical Trials

We are pleased to announce that on February 2023, our research project received approval from WIRB-Copernicus Group (WCG) for our multicenter clinical trial central IRB. This milestone is a testament to our commitment to ethical research practices and our project's potential impact. With this approval, we are poised to move forward with our study, adhering to the highest standards of research integrity and participant safety. This achievement brings us one step closer to realizing our research goals and making a meaningful difference for NAS-affected babies.